Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


B&L exec sanctioned

This article was originally published in The Tan Sheet

Executive Summary

President & CEO Ronald Zarrella will "forfeit any annual incentive bonuses for 2002, of which $1.1 mil. was guaranteed under his employment agreement," due to misrepresentation on his resume that he received an MBA (1"The Tan Sheet" Oct. 28, 2002, p. 13). In an 2Oct. 29 letter, Bausch & Lomb's Board of Directors does not accept his resignation, noting "we continue to believe [Zarrella is] the right person to carry on the resurgence of the company"...

You may also be interested in...

Sales & Earnings In Brief

Perrigo: Vitamin sales rose 6% in fiscal Q1, outpacing gains in the overall market (2%) and store brands (5%), private labeler says, citing IRI data during Oct. 24 analysts call. "Led by bone health and women's health products, we continued to hold our own in a weak market," Exec VP & CFO Douglas Schrank asserts. Cough/cold/allergy sales gained 9% compared to overall market (up 1%), store brands (down 1%). Company expects negative impact in fiscal Q3 from launch of OTC loratadine (Schering-Plough's Claritin) by other companies, but positive turn in Q1 of fiscal 2004 with its own loratadine offering. Perrigo does not hold "first-to-file" status for any generic loratadine dosage form. First quarter sales fell 1.8% to $213.2 mil., due in part to difficult comparison to year-ago sell-in of famotidine. Net income jump of 52.9% to $20 mil. attributed to manufacturing efficiencies, improved pricing, vitamin settlement proceeds, 1Perrigo press release says...

TytoCare Raised $50m In Funding Amid Rising Demand To Remotely Monitor COVID-19 Patients

TytoCare has raised $50m in funding, which will be used to expand the reach of its telehealth solutions.

A Bad Tip: Boston Scientific Recalls Thousands Of Catheters In Class I Recall

Boston Scientific has recalled more than 6,000 angiographic catheters because the tip can fall off and get stuck in patients, potentially causing serious injury or death. The company says customers should immediately stop using the lots associated with the faulty products and return them.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts